When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of antibody-drug conjugates (ADCs).
- Home |
- GSK CEO’s ‘scientific courage’ propels plans for medley of phase 3 trials for Hansoh-partnered ADC
GSK CEO’s ‘scientific courage’ propels plans for medley of phase 3 trials for Hansoh-partnered ADC
- April 10, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
